Biologic Adjuvants for the Management of Osteochondral Lesions of the Talus. Issue 3 (1st February 2019)

• Record Type: Journal Article
• Authors: Hogan, MaCalus V.; Hicks, Justin J.; Chambers, Monique C.; Kennedy, John G.
• Is Part Of: Journal of the American Academy of Orthopaedic Surgeons. Volume 27:Issue 3(2019)
• Publication Date: 2019-02-01
• Subjects: Orthopedics -- Periodicals; Orthopedic surgery -- Periodicals; Joint Diseases -- Periodicals; Orthopedics -- Periodicals; Orthopedic surgery; Orthopedics; Periodicals; 616.7005
• DOI: 10.5435/JAAOS-D-16-00840
• Languages: English
• ISSNs: 1067-151X

Abstract

Abstract : Surgical techniques for the management of recalcitrant osteochondral lesions of the talus have improved; however, the poor healing potential of cartilage may impede long-term outcomes. Repair (microfracture) or replacement (osteochondral transplants) is the standard of care. Reparative strategies lead to production of fibrocartilage, which, compared with the native type II articular cartilage, has decreased mechanical and wear properties. The success of osteochondral transplants may be hindered by poor integration between grafts and host that results in peripheral cell death and cyst formation. These challenges have led to the investigation of biologic adjuvants to augment treatment. In vitro and in vivo models have demonstrated promise for cartilage regeneration by decreasing inflammatory damage and increasing the amount of type II articular cartilage. Further research is needed to investigate optimal formulations and time points of administration. In addition, clinical trials are needed to investigate the long-term effects of augmentation.